TABLE 7.
Treatment response by zanubrutinib dose and disease type in Chinese patients with relapsed/refractory B‐cell malignancies
| Response category, n (%) | Zanibrutinab 160 mg BID | Zanibrutinib 320 mg QD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CLL/SLL, (n = 5) | NHL d , (n = 5) | WM, (n = 1) | Total, (N = 11) | CLL/SLL, (n = 4) | NHL d , (n = 5) | WM, (n = 1) | Total, (N = 10) | ||
| Overall response rate a | 5 (100.0) | 3 (60.0) | 0 (0.0) | 8 (72.7) | 4 (100.0) | 3 (60.0) | 1 (100.0) | 8 (80.0) | |
| 95% CI | (47.8–100.0) | (14.7–94.7) | (0.0–97.5) | (39.0–94.0) | (39.8–100.0) | (14.7–94.7) | (2.5–100.0) | (44.4–97.5) | |
| Partial response rate b | 4 (80.0) | 3 (60.0) | 0 (0.0) | 7 (63.6) | 4 (100.0) | 3 (60.0) | 1 (100.0) | 8 (80.0) | |
| 95% CI | (28.4–99.5) | (14.7–94.7) | (0.0–97.5) | (30.8–89.1) | (39.8–100.0) | (14.7–94.7) | (2.5–100.0) | (44.4–97.5) | |
| Complete response rate c | 2 (40.0) | 1 (20.0) | 0 (0.0) | 3 (27.3) | 1 (25.0) | 1 (20.0) | 0 (0.0) | 2 (20.0) | |
| 95% CI | (5.3–85.3) | (0.5–71.6) | (0.0–97.5) | (6.0–61.0) | (0.6–80.6) | (0.5–71.6) | (0.0–97.5) | (2.5–55.6) | |
Note: Zanubrutinib dose regimen is based on the first dose received. 95% CIs were calculated using the Clopper–Pearson method.
Abbreviations: BID, twice daily; CI, confidence interval; CLL/SLL, chronic lymphocytic leukaemia/small lymphocytic lymphoma; CR, complete response; FL, follicular lymphoma; MCL, mantle cell lymphoma; MR, minor response; MZL, marginal zone lymphoma; NE, not estimable; NHL, non‐Hodgkin lymphoma; PR, partial response; PR‐L, partial response with lymphocytosis; PD, progressive disease; QD, once daily; WM, Waldenström's macroglobulinaemia.
Overall response includes best overall response (of non‐stable disease, non‐PD, and non‐NE).
Partial response includes best overall response of PR or better (i.e., excluding PR‐L and MR).
Percentages are based on number of patients with best overall response being CR.
NHL includes FL, MZL and MCL.